GlaxoSmithKline ($GSK) put up $50 million of a $250 million life sciences fund, assembled by San Mateo, CA-based Sanderling Ventures, to help fill a geographic gap in their strategy to seed new biotech startups. Report
| Tuesday, March 17th | 11:30am ET / 8:30am PT | Presented by: Metabolon
Here we describe discovery approaches designed to broadly survey the skin metabolome as well as focused metabolomic assessment of sebum, stratum corneum, skin biopsy, cell culture and reconstructed skin models across a variety of conditions. Further, we share results from recent publications and practical clinical case studies. Register Now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!